Safety and Feasibility of YC‐6 in Patients With Large Hemispheric Infarction: A Randomized Clinical Trial
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.124.039157 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Huiqing Hou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation Medicine, Beijing Tiantan Hospital Capital Medical University Beijing China. Hauptthemen laut MEDLINE: Infarction, Middle Cerebral Artery, Brain Edema, Neuroprotective Agents. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Malignant cerebral edema is a critical cause of poor outcomes in large hemispheric infarction and novel neuroprotective agents are urgently needed. We aimed to assess the safety and preliminarily explored the feasibility of YC‐6 (5α‐androst‐3β,5,6β‐triol for injection) in large hemispheric infarction.
Methods
This study was a prospective, randomized, double‐blind, placebo‐controlled, proof‐of‐concept trial. Patients with large hemispheric infarction in middle cerebral artery within 12 hours of symptom onset were enrolled. Patients were assigned to receive either 300 mg YC‐6 or placebo twice a day for 10 days, randomly. The primary safety outcomes were serious adverse events and all‐cause death. The primary efficacy outcome was the distribution of the modified Rankin Scale score at 90 days.
Results
The incidence of serious adverse events (52.2% and 43.5%) and all‐cause death (39.1% and 40.0%) within 90 days were similar between YC‐6 and placebo group. There was no statistical difference between the groups in the distribution of modified Rankin Scale score (common odds ratio 0.73, 95% CI: 0.25 to 2.18). The proportion of a modified Rankin Scale score of 0 to 4 was 56.5% in YC‐6 group compared with 35.0% in placebo group ( P =0.16). In addition, YC‐6 treatment numerically alleviated edema volume at 72 hours and 10 days (RD −15.02, 95% CI: −40.94 to 10.90; RD −10.35, 95% CI: −46.69 to 25.98) and decreased midline shift at 10 days (RD −0.6, 95% CI: −4.17 to 2.97).
Conclusions
This study preliminarily explored the safety and feasibility of YC‐6 in patients with large hemispheric infarction. Based on this trial, the phase 2 trial of YC‐6 was worthy of anticipation. Registration http://www.chinadrugtrials.org.cn ; Unique identifier: CTR20192127; http://www.chictr.org.cn ; Unique identifier: ChiCTR2400088887.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rehabilitation Medicine, Beijing Tiantan Hospital Capital Medical University Beijing China.
- China National Clinical Research Center for Neurologic Diseases, Beijing Tiantan Hospital Capital Medical University Beijing China.
- Department of Neurology and Department of Clinical Trial Center, Beijing Tiantan Hospital Capital Medical University Beijing China.
ORCID-Profile: Huiqing Hou, Baoyu Feng, Zixiao Li, Yilong Wang, Xingquan Zhao, Yongjun Wang, Shuya Li
Zitieren
APA
Hou, H., Feng, B., Zang, D., Li, Z., Wang, Y., Zhao, X., Wang, Y., & Li, S. (2025). Safety and Feasibility of YC‐6 in Patients With Large Hemispheric Infarction: A Randomized Clinical Trial. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.039157
Vancouver
Hou H, Feng B, Zang D, Li Z, Wang Y, Zhao X, et al. Safety and Feasibility of YC‐6 in Patients With Large Hemispheric Infarction: A Randomized Clinical Trial. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.039157
BibTeX
@article{Hou2025,
author = {Hou, Huiqing and Feng, Baoyu and Zang, Dawei and Li, Zixiao and Wang, Yilong and Zhao, Xingquan and Wang, Yongjun and Li, Shuya},
title = {Safety and Feasibility of YC‐6 in Patients With Large Hemispheric Infarction: A Randomized Clinical Trial},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.039157}
}
EUVIMED